Founded in 2013, AblaCor (formerly known as Automated Medical Instruments, Inc.) is an early-stage medical device company located in a suburb of Boston, MA. Our first product is the AblaCor AF Catheter Ablation System to advance pulmonary vein isolation (PVI) procedures for patients with atrial fibrillation (AFib), the most common irregular heart rhythm and a potentially deadly disorder. The AblaCor system is designed to overcome limitations of currently available ablation catheters for AFib by producing durable, continuous, transmural lesions the first time. AblaCor has a strong portfolio of patents issued and pending.

Led by Martin Sklar, Founder and CEO, the AblaCor leadership team brings diverse expertise to the management of our company. From making decisions that guide long-term strategy to day-to-day operations, our team combines valuable medical technology leadership and R&D experience that is creating a game-changing technology.


Martin Sklar, founder & CEO

AblaCor is led by Martin Sklar, a highly accomplished Leader, Inventor, Consultant and Engineer. He has extensive experience in business development, intellectual property development, project management, design engineering, manufacturing engineering, technical analysis, and product introduction in the medical technology industry. He founded Automated Medical Instruments, Inc. in 1992, now AblaCor Medical Corporation as of January 2013, to focus on developing remote-controlled instruments for minimally invasive medical applications, including the present business to treat Atrial Fibrillation. 

​Mr. Sklar’s accomplishments have contributed to over $1 Billion in revenues for clients and employers from start-up through Fortune 100 companies. He has 10 issued patents and 10 patents pending. In 2001, Martin co-founded the nonprofit organization, Medical Development Group (MDG), a major New England based medical technology industry association. He was its first president and a board member until 2012. In 2002, he co-founded AlvaMed, LLC. In 2006, he co-founded Medical Development Partners, LLC., both medical technology consulting companies.

Mr. Sklar exhibits profound interest in medical automation and robotics. He has given his presentation, ‘Improving Healthcare Outcomes and Reducing Costs through Medical Automation,’ to numerous audiences. He is a member of several professional associations including MDG, Heart Rhythm Society, and the Biomedical Engineering Society. His education includes a Master of Engineering degree from Dartmouth College’s Thayer School of Engineering, and a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute. ​ 

Jim Bricker, MBA Business Advisor

Jim has served as President & CEO of six high tech companies, two of which he founded, and as a business consultant, aiding start-ups in the business planning and fundraising stages. Early in his career, he worked for three Fortune 500 companies. The products and services with which he has been involved range from electromechanical and electronic products (including aircraft security systems and interactive “talking” world globes) to hospital products (including catheters) to software products (including hospital emergency room triage software). He has successfully engaged individual investors, Angel groups and Venture Capital groups in his companies, and received investments from large companies as well as managed the sale of small companies to large companies in the course of his business career. Mr. Bricker was involved with the MIT Enterprise Forum almost from its inception, and has been an active member of the Harvard Business School Alumni Association. Most recently, Mr. Bricker has served as a Financial Advisor for the Bulfinch Group in Needham, Massachusetts. He holds two Bachelor’s degrees from M.I.T.: a B.S. in Mechanical Engineering and a B.S. in Management (from the Sloan School); as well as an MBA from the Harvard Business School.

Joyce College, MBA, RN, Director of Strategic Management

Joyce has demonstrated leadership in strategic planning, clinical marketing, program and product management, and commercialization. She has a passion for innovation in medical technology and the value it brings to patients, clinicians and the healthcare system. Ms. College has been a consultant and medical writer for Covidien. She has worked as a clinical marketing consultant for medical device companies and was a principal of Medical Development Partners, LLC, a medical product development and commercialization company. For over 16 years, she was a product and program manager for Fresenius Medical Care North America, the world leader in the manufacture and delivery of dialysis products and services. While at Fresenius, Ms. College had the opportunity to launch several significant treatments for renal patients including the drug, Epogen® and diagnostic services for the Dialysis Services Division. She has served as Vice President, Secretary and Board Member of the Medical Development Group (MDG), a major industry association and led several task forces and strategic efforts for the organization. Ms. College is also a member of Women in Healthcare Management, the American Nephrology Nurses Association and formerly on the Life Science Committee of the New England Israel Business Council. She holds a BS with a Major in Nursing and an MBA in Healthcare Management, both from Boston University.

Robert Flaherty, Business Advisor

Bob has served as President and Chief Executive Officer of Athena Diagnostics, Inc., a subsidiary of Thermo Fisher Scientific, Inc.. With $100M+ in revenue and $55M in EBITDA, Athena Diagnostics, was one of the nation’s largest, most profitable and fastest growing specialty commercial reference laboratories. Athena identified, developed, launched and marketed directly to physicians 320 innovative and proprietary diagnostic testing services. Mr. Flaherty was President of Becton Dickinson Medical, the largest and most profitable operating unit of Becton Dickinson & Company, along with Becton Dickinson’s worldwide operating unit, Vacutainer Systems. Mr. Flaherty has served on the Boards of Directors and has been chairman of the compensation committees and a member of the audit committees of Datatrak International, AngioDynamics, Inc., Xtent, Inc., Repromedix, Inc. all on NASDAQ as well as Synthes, Inc., then privately held, but now part of Johnson & Johnson Family of Companies, and Atherotech, Inc. He has a B.S. in Industrial Engineering from Lehigh University and an MBA from Harvard Business School.

Jeremy N. Ruskin, MD

Dr. Ruskin is the Founder and Director Emeritus of the Cardiac Arrhythmia Service at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Ruskin received his undergraduate degree from Tufts University and his medical degree from Harvard Medical School. He completed his residency in Internal Medicine at Beth Israel Hospital in Boston and his fellowship in Cardiovascular Disease at the Massachusetts General Hospital. He received his training in clinical cardiac electrophysiology at the USPHS Hospital in Staten Island, New York under the mentorship of Dr. Anthony Damato. In 1978, Dr. Ruskin founded the first cardiac arrhythmia service and clinical electrophysiology laboratory in New England and one of the first such services in the United States. As founder and director of the Massachusetts General Hospital Fellowship Training Program in Clinical Cardiac Electrophysiology, he has been responsible for the training and mentorship of more than 115 clinical and research fellows in the subspecialty of cardiac arrhythmias over the past 38 years, many of whom are in leadership positions at academic centers throughout the world. His major research interests include the mechanisms and management of atrial fibrillation, new antiarrhythmic drugs and innovative technologies for catheter ablation of atrial fibrillation, the mechanisms and prevention of ventricular arrhythmias and sudden cardiac death, risk stratification for sudden death, the role of arrhythmia control devices in the prevention of sudden cardiac death, the proarrhythmic effects of cardiac and non-cardiac drugs and cardiac safety issues in new drug and device development. He is an author of more than 450 original scientific publications, chapters, reviews, and monographs. Dr. Ruskin is the recipient of the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology, the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award and the 2015 KCHRS Pioneer in Electrophysiology Award. He was named the inaugural incumbent of the Omran Alomran Endowed Chair in Cardiology at Massachusetts General Hospital in 2016.​

Lawrence S. Rosenthal MD, PhD, FACC, FHRS

Dr. Rosenthal is Director, Cardiac Devices and Electrophysiology at the University of Massachusetts Memorial Medical Center. He is also affiliated with Webster Medical Center. His clinical interests include drug and ablation therapies for supraventricular and ventricular arrhythmias, including atrial fibrillation and ischemic VT, cardiac devices including ICD's and pacemakers, lead explantation, device therapy for heart failure including cardiac resynchronization. Dr. Rosenthal received his medical degree from Albert Einstein College of Medicine of Yeshiva University, his training in medicine from UMass Medical Center, and his training in cardiology at the John Hopkins Hospital. He and has been in practice for 16 years.

"Ablacor’s novel approach of a circular ablator, with its controlled electrode-tissue contact, designed to generate continuous and transmural ablation lesions reliably, holds great promise and would be a major advance."

The AblaCor AF Catheter Ablation System is not approved for human use.